Apolipoprotein E ε4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer disease
Adam Fleisher(Banner Alzheimer’s Institute), Eric M. Reiman(Alzheimer's Association), Carl Sadowsky(Nova Southeastern University), Xiaofen Liu(Alzheimer's Association), Hillary Protas(Alzheimer's Association), Auttawut Roontiva(Alzheimer's Association), Daniel Skovronsky(Eli Lilly (United States)), Robert E. Coleman(University of Sheffield), Michael J. Pontecorvo(Eli Lilly (United States)), Mark A. Mintun(Washington University in St. Louis), Napatkamon Ayutyanont(Alzheimer's Association), Keith A. Johnson(Brigham and Women's Hospital), Kewei Chen(Good Samaritan Medical Center), Christopher M. Clark(Institute on Aging), Marwan N. Sabbagh(Cleveland Clinic), Alan Carpenter, P. Murali Doraiswamy(Alzheimer’s Disease Neuroimaging Initiative), Reisa A. Sperling(Harvard University), Abhinay D. Joshi, Pradeep Thiyyagura(Alzheimer's Association)
Cited by 210
Related Papers
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
|Alzheimer s & Dementia|2018|10.4k
Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
|Alzheimer s & Dementia|2011|7.1k
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
|New England Journal of Medicine|2012|3.8k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease
|Alzheimer s & Dementia|2014|3.1k